To further test that CD44v6-regulated WNT/β-catenin signaling affects resistance in response to FOLFOX, FOLFOX resistant SW480-FR tumor cell viability was assayed using different doses of FOLFOX in the presence or absence of two different sets of shRNAs (shRNA1 and shRNA2) targeted to CD44v6 and WNT3A (CD44v6 shRNA1/2, or WNT3A shRNA1/2, and CD44v6 shRNA1/2 plus pCD44v6 cDNA) (Figures 2F, G). This evidence concerns the gene WNT3A and neoplasm.